INSM Stock Price Today (September 2026) — Insmed Incorporated Analysis & Key Metrics 2026-09-03
Insmed Incorporated (INSM) is trading at $126.68, up 0.04% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $200.18 (58.0% upside).
- Volatility remains elevated (31.23% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.96% YoY) alongside significant competitive pressures.
INSM Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Insmed Incorporated - Historical Price & Volume
Market Cap
Enterprise Value: $25.47B
P/E Ratio
Forward P/E: 151.85
Revenue Growth
Year over Year
Analyst Target
+58.0% upside potential
Key Investor Questions About INSM
What investors need to know before buying
Based on current market data, INSM presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 59.73)
- Fundamentals say: Caution warranted (high leverage concerns)
INSM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for INSM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $739.72M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, INSM stock traded between $90.39 and $212.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 31.23% annualized volatility and β=0.61, the stock exhibits low sensitivity to market moves—making INSM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent […]
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of […]
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Insmed (INSM) Q2 2026 Earnings Call Transcript
BRINSUPRI revenue surged to $309.2 million, driving total revenues to $425.5 million.
What Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
Has Insmed (INSM) Risen Above Fair Value After Its 3 Year Run?
Insmed stock has delivered a very large 3 year return, yet the current valuation checks and market multiples point to a price that leans expensive rather than clearly cheap. Insmed has returned roughly 4.8x over the past 3 years, which puts the recent performance firmly in the spotlight for anyone thinking about new money going in at current levels. Expectations around the company’s rare disease therapy pipeline can support the current price, while execution risk in ongoing clinical...
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Insmed Incorporated Q2 2026 Earnings Call Summary
Moby summary of Insmed Incorporated's Q2 2026 earnings call
US Stock Market Today S&P 500 Futures Edge Higher On Mixed Growth Signals
The Morning Bull - US Market Morning Update Friday, Aug, 7 2026 US stock futures are slightly higher this morning, with E mini S&P 500 contracts up about 0.2%, as investors weigh strong services activity against softer hiring and shifting interest rate expectations. The composite PMI for July sits at 54.5, which is a broad scorecard showing private sector growth at a nine month high. However, input costs are at a 14 month high, so the cost of doing business is still rising. At the same time,...
Explore More Analysis for INSM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Insmed Incorporated
Insmed Incorporated (INSM) is currently trading at $126.68. The RSI (14-day) is at 59.7, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $200.18 implies 58.0% upside from current levels. Volatility is moderate at 31.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insmed Incorporated (INSM): The trailing P/E ratio is -29.88, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 151.85. Price-to-Book is 36.51. Price-to-Sales is 24.32. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering INSM, the consensus price target is $200.18. This represents a 58.0% upside from the current price of $126.68. The range spans from a low target of $169.00 to a high target of $243.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insmed Incorporated (INSM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insmed Incorporated (INSM) investors include: 1. Moderate volatility (31.2% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insmed Incorporated's (INSM) current debt and financial health profile: Total debt stands at $739.72M. The debt-to-equity ratio is 97.65, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.72, indicating strong short-term liquidity. The quick ratio is 3.13. The company holds $1.16B in cash and equivalents. Free cash flow is negative at $-571,815,616, which could limit the company's ability to manage debt obligations.